Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biophytis ( (BPTSY) ) has provided an update.
On August 28, 2025, Biophytis SA announced it received regulatory approval from the European Medicines Agency and Belgian authorities to initiate a Phase 3 clinical trial for sarcopenia. This approval allows Biophytis to begin patient enrollment in Belgium and collaborate with clinical centers across Europe, marking a significant milestone in their efforts to develop therapies for muscle loss due to aging.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Underperform.
Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Their lead drug candidate, BIO101, is aimed at treating muscular diseases like sarcopenia and metabolic disorders such as obesity. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Biophytis’ shares are listed on Euronext Growth Paris and its ADS are listed on the OTC market.
Technical Sentiment Signal: Sell
Current Market Cap: $4.64M
For detailed information about BPTSY stock, go to TipRanks’ Stock Analysis page.